Published in AIDS Weekly, October 25th, 1999
Additionally, the company announced it has completed a private placement of common stock resulting in proceeds of $25 million to the company, enabling the company to expand its vaccine research to develop HIV vaccines for worldwide eradication of AIDS.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.